Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051377 | 0.86 | AR (0.76) | ARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17014714 | 0.84 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL20299007 | 0.81 | AR (0.67) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL22263374 | 0.80 | AR (0.66) | ARNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17266277 | 0.77 | AR (0.61) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL2499085 | 0.76 | NPC1 (0.60) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL17014742 | 0.76 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL20299015 | 0.75 | AR (0.60) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL17014744 | 0.74 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL17014741 | 0.74 | AR (0.77) | ARNPC1RAB9ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031848-A1 | AR-V7 INHIBITORS | HOFFMANN LA ROCHE (US) | 2020-01-30 | — | — | US | claimed |
| EP-3555091-A1 | AR-V7 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-23 | — | — | EP | claimed |
| WO-2018114781-A1 | AR-V7 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-28 | — | — | WO | claimed |
| US-20200031848-A1 | AR-V7 INHIBITORS | HOFFMANN LA ROCHE (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200031848-A1 | AR-V7 INHIBITORS | HOFFMANN LA ROCHE (US) | 2020-01-30 | — | — | US | disclosed |
| EP-3555091-A1 | AR-V7 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| WO-2018114781-A1 | AR-V7 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-28 | — | — | WO | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| WO-2015120543-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAIN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031848-A1 | AR-V7 INHIBITORS | AR, RB1, NR5A1 | AR 1/4885NPC1 2126/4885RAB9A 974/4885 |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | AR 1/4885NPC1 2934/4885RAB9A 4667/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | AR 1/4885NPC1 1960/4885RAB9A 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.